DOES YOUR CLINICAL INVESTIGATOR UNDERSTAND THE CONSEQUENCES OF NON-COMPLIANCE?

The increasing number and complexity of clinical trials, coupled with the recent increase in attention and enforcement from the U.S. Food and Drug Administration, arguably makes it more important than ever before that clinical investigators understand the regularatory requirements with which they mu...

Full description

Saved in:
Bibliographic Details
Published in:Quality assurance (San Diego, Calif.) Calif.), 2000-07, Vol.7 (3), p.135-145
Main Authors: Donato, Brian J., Gibson, Thomas R.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The increasing number and complexity of clinical trials, coupled with the recent increase in attention and enforcement from the U.S. Food and Drug Administration, arguably makes it more important than ever before that clinical investigators understand the regularatory requirements with which they must comply. This article outlines some of these requirements, common areas of non-compliance and FDA's enforcement options in dealing with such non-compliance. Finally, the article provides some suggestions for attaining and managing investigator compliance.
ISSN:1052-9411
1521-0677
DOI:10.1080/105294100750035116